Summary & Overview

CPT 0263U: NPDX ASD and Central Carbon Energy Metabolism Plasma Test

CPT code 0263U designates a Proprietary Laboratory Analyses (PLA) test — the NPDX ASD and Central Carbon Energy Metabolism assay from Stemina Biomarker Discovery Inc. The test analyzes 16 central carbon metabolites from a plasma specimen and uses an algorithm to detect metabolic patterns consistent with autism spectrum disorder (ASD). As a PLA code, 0263U applies to a single manufacturer's unique test and is relevant to payers, laboratories, and clinicians managing ASD diagnostic pathways that incorporate metabolic biomarker data.

Key payers in national coverage discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code's clinical purpose and service setting, payers commonly engaged in coverage determinations, and the types of benchmarks and policy considerations typically associated with PLA laboratory codes. The publication provides context on the test's role in ASD evaluation, payer engagement for proprietary assays, and areas where payers and laboratories commonly align or diverge on coverage policy. Data not available in the input will be identified as such in relevant sections.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0263UCPTProprietary Laboratory AnalysesASDCentral Carbon MetabolismPlasma TestLaboratory MedicineBiomarker

Billing Code Overview

CPT code 0263U is a Proprietary Laboratory Analyses (PLA) code for the NPDX ASD and Central Carbon Energy Metabolism test developed by Stemina Biomarker Discovery Inc. The test uses a plasma specimen to measure 16 central carbon metabolites and applies an algorithmic analysis to identify a pattern of metabolic imbalance consistent with an autism spectrum disorder (ASD) diagnosis.

Service Type: Clinical laboratory analysis with algorithmic/interpretive reporting

Typical Site of Service: Clinical laboratory or reference lab (specimen collected in an outpatient or ambulatory setting and sent to the performing laboratory)

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A pediatric or adult patient with developmental concerns or suspected autism spectrum disorder (ASD) is referred for metabolic biomarker evaluation. The clinician (commonly a developmental pediatrician, pediatric neurologist, child psychiatrist, or clinical geneticist) orders the NPDX ASD and Central Carbon Energy Metabolism test to assess plasma levels of 16 central carbon metabolites and an algorithmic pattern analysis to identify a metabolic signature consistent with ASD. Blood is collected as a plasma specimen in an outpatient laboratory or hospital phlebotomy suite (typical site of service: outpatient clinical laboratory or hospital outpatient department). The sample is processed per the laboratory’s specimen requirements and shipped to Stemina Biomarker Discovery Inc. for proprietary analysis. Results are returned to the ordering clinician and integrated with clinical history, behavioral assessments, and other diagnostic studies to inform diagnostic formulation, further metabolic testing, or care planning. Typical clinical workflow steps: specimen collection and proper labeling, completion of test requisition with patient identifiers and clinical indication, billing using PLA code 0263U, laboratory processing and shipment, receipt of a proprietary report from the performing lab, and clinician review during follow-up visit to discuss findings with family or caregiver.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no specific modifier applies and service is billed without professional or technical component distinctions.
`26`	Professional component	Use when billing only the professional component (interpretation) if the laboratory reports split billing between professional and technical components.
`TC`	Technical component	Use when billing only the technical component (laboratory processing and analysis) performed by the lab.
`52`	Reduced services	Use when the service provided is partially reduced or not performed to full extent.
`53`	Discontinued procedure	Use when specimen collection or testing was started but discontinued for documented clinical reasons.
`59` is NOT in the provided list and therefore not included	---	---
`QX`	Ordering physician NP/PA modifier	Use when a nurse practitioner or physician assistant with independent billing orders the test and applicable payor rules require identification of practitioner type.
`QY`	Ordering/referring physician modifier	Use when the performing lab needs to indicate the test was ordered by an eligible referring physician under specific payor rules.
`QK`	Medical direction of two, three, or four services	Use if applicable when multiple supervising physicians are involved in direction of the testing services (rare for PLA testing).
`QK`	---	---
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for Medicare beneficiaries furnished as a primary care or psychiatric collaborative care service	Use per specific payor billing policies when an APP is responsible for ordering or managing the test.
`FY`	Left unspecified by CMS in general modifier lists; used by some payors for special billing situations	Use as directed by the performing laboratory’s payor contracts where applicable.
`QX`	---	---

Taxonomy Code	Specialty	Notes
2080P0207X	Developmental-Behavioral Pediatrician	Common ordering specialist for ASD-related metabolic testing.
208000000X	Pediatrician	Frequently orders laboratory testing for developmental concerns.
207RG0100X	Neurology (Pediatric)	Orders metabolic panels in neurological evaluation of developmental delay.
2084P0800X	Medical Genetics	Orders and interprets metabolic and genetic testing in ASD workups.
208200000X	Clinical Laboratory Director	Oversees laboratory performing the technical component and reporting of `0263U`.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F84.0`	Autistic disorder	Primary diagnosis commonly associated with ordering ASD metabolic biomarker testing to support diagnostic evaluation.
`F84.5`	Asperger syndrome	Related autism spectrum condition where metabolic testing may be considered in diagnostic workup.
`R62.0`	Delayed milestone in childhood	Developmental delay prompting metabolic evaluation including specialized assays.
`F80.9`	Developmental speech or language disorder, unspecified	Communication deficits that may trigger broader developmental and metabolic testing.
`F82`	Specific developmental disorder of motor function	Motor delays often co-evaluated with metabolic and neurologic testing.
`F84.9`	Pervasive developmental disorder, unspecified	Used when ASD features are present but specific subtype is not specified.
`E88.9`	Metabolic disorder, unspecified	General metabolic concerns that align with ordering central carbon metabolism assays.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0362U`	Proprietary Laboratory Analyses; [example PLA code] (placeholder description)	Data not available in the input.
`80053`	Comprehensive metabolic panel	Often performed before or alongside specialized metabolic testing to assess basic metabolic status.
`82043`	Vitamin B12; serum	May be included in broader metabolic assessments relevant to neurodevelopmental conditions.
`82306`	Vitamin D; 25 hydroxy	Common adjunct lab in developmental assessments for overall health status.
`81479`	Unlisted molecular pathology procedure	May be used for additional laboratory genomic tests when no specific code exists.

Note: The input did not provide related CPT codes. The table above lists commonly associated laboratory and molecular codes that may be ordered in the clinical workflow surrounding a proprietary ASD metabolic assay.